In vivo fluorescence-based endoscopic detection of XXXX in the @entity19 using a novel peptide probe.

@entity652 @entity5 @entity75 @entity19 @entity5072 @entity11518 @entity6523 @entity14 @entity1586 @entity1412 @entity694 @entity6349 @entity1049
@entity14 ( @entity14 ) is a major cause of @entity5 in much of the world. Most CRCs arise from pre-malignant ( @entity6349 ) lesions, such as @entity6523 , and current endoscopic screening approaches with white light do not detect all @entity75 . Thus, new strategies to identify such lesions, including @entity75 , are needed. We aim to identify and validate novel peptides that specifically @entity1049 in vivo. We used phage display to identify a novel peptide that binds to @entity694 in vivo in a genetically engineered @entity19 model of colo-rectal tumorigenesis, based on somatic @entity1412 ( @entity1412 ) gene inactivation. Binding was confirmed using confocal microscopy on biopsied @entity652 and excised @entity652 incubated with peptide ex vivo. Studies of @entity19 where a mutant @entity11518 allele was somatically activated in the colon to generate @entity5072 epithelium were also performed for comparison. Several rounds of in vivo T7 library biopanning isolated a peptide, QPIHPNNM. The fluorescent-labeled peptide bound to @entity75 on endoscopic analysis. Quantitative assessment revealed the fluorescent-labeled peptide (target/background: 2.17  0.61) binds    2-fold greater to the @entity1586 when compared to the control peptide (target/background: 1.14  0.15), p<0.01. The peptide did not bind to the non- @entity6349 ( @entity5072 ) epithelium of the @entity11518 @entity19 . This work is first to image fluorescence-labeled peptide binding in vivo that is specific towards @entity694 on wide-area surveillance. This finding highlights an innovative strategy for targeted detection to localize pre-malignant lesions that can be generalized to the epithelium of hollow organs.
